UTAH MEDICAL PRODUCTS INC 10-Q/A

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds During 9M 2020, UTMD purchased 87,000 of its shares in the open market for $6,977 including commissions and fees. During 9M 2019 UTMD purchased 5,000 of its shares in the open market for $398 including commissions and fees. Item 6. Exhibits Exhibit # Title of Document 31.1 Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2 Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1 Certification of CEO pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2 Certification of Principal Financial Officer pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101 The following financial information from the Utah Medical Products, Inc. quarterly report on Form 10-Q for the quarter ended September 30, 2020, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Consolidated Condensed Balance Sheets, (ii) Consolidated Condensed Statements of Income, (iii) Consolidated Condensed Statements of Cash Flows, (iv) Consolidated Statements of Stockholders’ Equity, and (v) related Notes to the Consolidated Condensed Financial Statements, tagged in detail. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 20 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. UTAH MEDICAL PRODUCTS, INC. REGISTRANT Date: 11/9/20 By: /s/ Kevin L. Cornwell Kevin L. Cornwell CEO Date: 11/9/20 By: /s/ Brian L. Koopman Brian L. Koopman Principal Financial Officer 21